Evidence map›Paper›PMID 36579550›Full record

ArticleThe journal of pathology. Clinical research2023

A novel NGS-based diagnostic algorithm for classifying multifocal lung adenocarcinomas in pN0M0 patients.

Xin Zhang, Xiaoxi Fan, Changbo Sun, Liang Wang, Yuan Miao, Liming Wang, Peng Yang, Yang Xu, Xue Ren, Xue Wu and 1 more

Open access · goldAbstract read
In one paragraph

Article in The journal of pathology. Clinical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 3 countries.

Xin ZhangDepartment of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, PR China.
Xiaoxi FanDepartment of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, PR China.
Changbo SunDepartment of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, PR China.
Liang WangDepartment of Pathology, The First Hospital of China Medical University, Shenyang, Liaoning, PR China.
Yuan MiaoDepartment of Pathology, The First Hospital of China Medical University, Shenyang, Liaoning, PR China.ORCID 0000-0001-7869-8099
Liming WangDepartment of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, PR China.
Peng YangGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, PR China.
Yang XuGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, PR China.ORCID 0000-0003-1670-6131
Xue RenGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, PR China.
Xue WuGeneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, Jiangsu, PR China.
Shun XuDepartment of Thoracic Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, PR China.
First Hospital of China Medical University · CNGenesee Community College · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The classification of multifocal lung adenocarcinomas (MLAs), including multiple primary lung adenocarcinomas (MPLAs) and intrapulmonary metastases (IPMs), has great clinical significance in staging and treatment determination. However, the application of molecular approaches in pN0M0 MLA diagnosis has not been well investigated. Here, we performed next-generation sequencing (NGS) analysis in 45 pN0M0 MLA patients (101 lesion pairs) who were initially diagnosed as having MPLA by comprehensive histologic assessment (CHA). Five additional patients with intrathoracic metastases were used as positive controls, while 197 patients with unifocal lung adenocarcinomas (425 random lesion pairs) were used as negative controls. By utilizing a predefined NGS criterion, all IPMs in the positive control group could be accurately classified, whereas 13 lesion pairs (3.1%) in the negative control cohort were misdiagnosed as IPMs. Additionally, 14 IPM lesion pairs were diagnosed in the study group, with at least 7 misdiagnoses. We thus developed a refined algorithm, incorporating both NGS and histologic results, that could correctly diagnose all the known MPLAs and IPMs. In particular, all IPMs identified by the refined algorithm were diagnosed to be IPMs or suspected IPMs by CHA reassessment. The refined algorithm-diagnosed MPLAs patients also had significantly better progression-free survival than the refined algorithm-diagnosed IPMs (p < 0.0001), which is superior to conventional NGS or CHA diagnoses. Overall, we developed an NGS-based algorithm that could accurately distinguish IPMs from MPLAs in MLA patients. Our results demonstrate a promising clinical utility of NGS to complement traditional CHA-based MLA diagnosis and help determine patient staging and treatment.

Indexed as

Adenocarcinoma of LungLung NeoplasmsAlgorithmsHigh-Throughput Nucleotide SequencingHumansLungcomprehensive histologic assessmentintrapulmonary metastasismultifocal lung adenocarcinomamultiple primary lung adenocarcinomanext-generation sequencing

Identifiers

PMID36579550
PMCPMC9896159
OpenAlexW4313277428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.